Home LiteratureArticle Details
PMID: 19125209 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder.

Journal of psychiatry & neuroscience : JPN ·Vol. 34 ·No. 1 ·2009-01-00 ·Pages 4-20

Anisman H

Abstract

Activation of the inflammatory immune system provokes numerous neuroendocrine and neurotransmitter changes, many of which are similar to those provoked by physical or psychological stressors. These findings, among others, have led to the suggestion that the brain translates immune activation much as if it were a stressor. In this review, I provide synopses of the effects of traditional stressors on the release of corticotropin-releasing hormones at hypothalamic and extrahypothalamic sites, variations of serotonin and its receptors and changes of brain-derived neurotrophic factor (BDNF). These effects are similar to those elicited by activation of the inflammatory immune system, particularly the impact of the immune-signalling molecules interleukin-1 beta, interleukin-6, tumour necrosis factor-alpha and interferon-alpha on neuroendocrine, neurotransmitter and BDNF function. In addition, it is reported that stressors and cytokines may synergistically influence biological and behavioural processes and that these treatments may have long-term ramifications through the sensitization of processes associated with stress responses. Finally, I present an overview of the depressogenic actions of these cytokines in rodent models and in humans, and I provide provisional suggestions (and caveats) about the mechanisms by which cytokines and stressors might culminate in major depressive disorder.

MeSH Terms
Animals Brain Chemistry/physiology Cytokines/metabolism Depressive Disorder, Major/psychology Humans Immune System/physiology Inflammation/immunology,psychology Stress, Psychological/psychology
Chemicals
Cytokines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Anisman Hymie
Institute of Neuroscience, Carleton University, Ottawa, Ontario, Canada. [email protected]
References (236)
236 references, click to expand
  1. Lipopolysaccharide has indomethacin-sensitive actions on Fos expression in topographically organized subpopulations of serotonergic neurons.
    Brain Behav Immun. 2006 Nov;20(6):569-77 PMID: 16554144
  2. Differential effects of acute and chronic social defeat stress on hypothalamic-pituitary-adrenal axis function and hippocampal serotonin release in mice.
    J Neuroendocrinol. 2006 May;18(5):330-8 PMID: 16629831
  3. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions.
    Endocr Rev. 2000 Feb;21(1):55-89 PMID: 10696570
  4. Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells.
    Mol Pharmacol. 1996 Nov;50(5):1103-10 PMID: 8913341
  5. Inflammation and brain edema: new insights into the role of chemokines and their receptors.
    Acta Neurochir Suppl. 2006;96:444-50 PMID: 16671502
  6. The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats.
    Behav Brain Res. 2007 Aug 22;182(1):80-7 PMID: 17588681
  7. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment.
    Neuroscience. 1999;88(3):823-36 PMID: 10363820
  8. Previous experience with behavioral control over stress blocks the behavioral and dorsal raphe nucleus activating effects of later uncontrollable stress: role of the ventral medial prefrontal cortex.
    J Neurosci. 2006 Dec 20;26(51):13264-72 PMID: 17182776
  9. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors.
    Biol Psychiatry. 2007 Jan 15;61(2):187-97 PMID: 16697351
  10. Neurobiology of depression.
    Neuron. 2002 Mar 28;34(1):13-25 PMID: 11931738
  11. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats.
    Eur J Neurosci. 2001 Jan;13(2):373-80 PMID: 11168542
  12. Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections).
    J Neuroimmunol. 2004 Feb;147(1-2):43-9 PMID: 14741426
  13. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression.
    J Viral Hepat. 2005 Jan;12(1):96-100 PMID: 15655055
  14. Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain.
    Life Sci. 2000;66(6):PL93-8 PMID: 10794073
  15. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity.
    Neuroscience. 2005;135(3):659-78 PMID: 16154288
  16. Effects of stress on the functional properties of pre- and postsynaptic 5-HT1B receptors in the rat brain.
    Eur J Pharmacol. 1995 Dec 29;294(2-3):531-40 PMID: 8750715
  17. Angst and the amygdala.
    Dialogues Clin Neurosci. 2006;8(4):407-16 PMID: 17290799
  18. Central cyclic-AMP-linked noradrenergic receptors: new findings on properties as related to the actions of stress.
    Neurosci Biobehav Rev. 1987 Winter;11(4):391-8 PMID: 2830565
  19. Does amygdaloid corticotropin-releasing hormone (CRH) mediate anxiety-like behaviors? Dissociation of anxiogenic effects and CRH release.
    Eur J Neurosci. 2004 Jul;20(1):229-39 PMID: 15245495
  20. Repeated co-treatment with imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats.
    J Physiol Pharmacol. 2007 Jun;58(2):219-34 PMID: 17622693
  21. Role of neurotrophic factors in depression.
    Curr Opin Pharmacol. 2007 Feb;7(1):18-21 PMID: 17049922
  22. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression.
    Mol Psychiatry. 2008 Jul;13(7):717-28 PMID: 17700577
  23. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.
    Aliment Pharmacol Ther. 2002 Jun;16(6):1091-9 PMID: 12030950
  24. Phenotypic plasticity of CRF neurons during stress.
    Ann N Y Acad Sci. 1993 Oct 29;697:39-52 PMID: 8257021
  25. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
    J Hepatol. 2005 Jun;42(6):793-8 PMID: 15885349
  26. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.
    Psychosomatics. 2003 Mar-Apr;44(2):104-12 PMID: 12618532
  27. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.
    J Psychosom Res. 2005 Jan;58(1):15-8 PMID: 15771865
  28. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission.
    Neuroscience. 2005;133(2):519-31 PMID: 15878644
  29. Chronic treatment with the antidepressant tianeptine attenuates lipopolysaccharide-induced Fos expression in the rat paraventricular nucleus and HPA axis activation.
    Psychoneuroendocrinology. 2003 Jan;28(1):19-34 PMID: 12445834
  30. Sensitization to the effects of tumor necrosis factor-alpha: neuroendocrine, central monoamine, and behavioral variations.
    J Neurosci. 1999 Jul 1;19(13):5654-65 PMID: 10377371
  31. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.
    J Clin Oncol. 2000 May;18(10):2143-51 PMID: 10811680
  32. Epigenetic mechanisms of perinatal programming of hypothalamic-pituitary-adrenal function and health.
    Trends Mol Med. 2007 Jul;13(7):269-77 PMID: 17544850
  33. Long-term down-regulation of BDNF mRNA in rat hippocampal CA1 subregion correlates with PTSD-like behavioural stress response.
    Int J Neuropsychopharmacol. 2007 Dec;10(6):741-58 PMID: 17291374
  34. Cytokine-induced sickness behavior: mechanisms and implications.
    Ann N Y Acad Sci. 2001 Mar;933:222-34 PMID: 12000023
  35. Interleukin 6 modulates interleukin-1-and stress-induced activation of the hypothalamic-pituitary-adrenal axis in male rats.
    Neuroendocrinology. 1996 Mar;63(3):227-36 PMID: 8677011
  36. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression.
    Am J Psychiatry. 2001 Apr;158(4):582-6 PMID: 11282692
  37. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress.
    Nat Neurosci. 2003 Oct;6(10):1100-7 PMID: 12973355
  38. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus.
    Neuropsychopharmacology. 2006 Dec;31(12):2619-26 PMID: 16823390
  39. Immunity and depression: insomnia, retardation, and reduction of natural killer cell activity.
    J Behav Med. 1994 Apr;17(2):217-23 PMID: 8035453
  40. Stress, depression, and anhedonia: caveats concerning animal models.
    Neurosci Biobehav Rev. 2005;29(4-5):525-46 PMID: 15925696
  41. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment.
    Biol Psychiatry. 2006 Jul 1;60(1):77-9 PMID: 16487941
  42. Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of sickness behavior in mice.
    Psychoneuroendocrinology. 1994;19(2):197-207 PMID: 8190839
  43. The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic.
    Med Hypotheses. 2000 Jan;54(1):126-30 PMID: 10790737
  44. Paroxetine for the prevention of depression induced by high-dose interferon alfa.
    N Engl J Med. 2001 Mar 29;344(13):961-6 PMID: 11274622
  45. Synergism between IL-1 beta and TNF-alpha on the activity of the pituitary-adrenal axis and on food intake of rats.
    Am J Physiol. 1995 Apr;268(4 Pt 1):E551-7 PMID: 7733251
  46. Mice overexpressing CRH show reduced responsiveness in plasma corticosterone after a5-HT1A receptor challenge.
    Genes Brain Behav. 2002 Aug;1(3):174-7 PMID: 12884973
  47. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants.
    Biol Psychiatry. 2003 Jul 1;54(1):70-5 PMID: 12842310
  48. Chronic stimulation of the hypothalamus-pituitary-adrenal axis in rats by interleukin 1beta: central and peripheral mechanisms.
    Cytokine. 1996 Dec;8(12):910-9 PMID: 9050749
  49. Synergistic and additive actions of a psychosocial stressor and endotoxin challenge: Circulating and brain cytokines, plasma corticosterone and behavioral changes in mice.
    Brain Behav Immun. 2008 May;22(4):573-89 PMID: 18191534
  50. alpha-MSH modulates local and circulating tumor necrosis factor-alpha in experimental brain inflammation.
    J Neurosci. 1997 Mar 15;17(6):2181-6 PMID: 9045742
  51. Cytokine-induced sickness behaviour: mechanisms and implications.
    Trends Neurosci. 2002 Mar;25(3):154-9 PMID: 11852148
  52. Neuroimmunomodulatory actions of hypothalamic interferon-alpha.
    Neuroimmunomodulation. 1998 May-Aug;5(3-4):172-7 PMID: 9730683
  53. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6.
    J Neurosci. 2002 Jan 15;22(2):486-92 PMID: 11784794
  54. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study.
    Eur Psychiatry. 2006 Apr;21(3):204-10 PMID: 16632167
  55. Evidence that conditioned stress enhances outflow of dopamine in rat prefrontal cortex: a search for the influence of diazepam and 5-HT1A agonists.
    Synapse. 1996 Nov;24(3):240-7 PMID: 8923664
  56. Central noradrenergic neurones and stress.
    Pharmacol Ther. 1995;68(2):297-42 PMID: 8719972
  57. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes.
    Brain Behav Immun. 2002 Oct;16(5):544-56 PMID: 12401468
  58. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents.
    Neuropsychopharmacology. 2001 May;24(5):531-44 PMID: 11282253
  59. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression.
    J Neurosci. 2002 Apr 15;22(8):3251-61 PMID: 11943826
  60. The role of IL-1beta in stress-induced sensitization of proinflammatory cytokine and corticosterone responses.
    Neuroscience. 2004;127(3):569-77 PMID: 15283957
  61. Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction.
    Neurobiol Aging. 2008 Sep;29(9):1380-93 PMID: 17467122
  62. Interaction between interferon gamma and insulin-like growth factor-1 in hippocampus impacts on the ability of rats to sustain long-term potentiation.
    J Neurochem. 2006 Mar;96(6):1560-71 PMID: 16464236
  63. Behavioral changes in rats after acute, chronic and repeated administration of interleukin-1beta: relevance for affective disorders.
    J Affect Disord. 2003 Nov;77(2):143-8 PMID: 14607391
  64. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.
    AIDS. 2005 Oct;19 Suppl 3:S174-8 PMID: 16251815
  65. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus.
    J Neurosci. 1995 Mar;15(3 Pt 1):1768-77 PMID: 7891134
  66. A neurotrophic model for stress-related mood disorders.
    Biol Psychiatry. 2006 Jun 15;59(12):1116-27 PMID: 16631126
  67. Medial prefrontal cortical D1 receptor modulation of the meso-accumbens dopamine response to stress: an electrochemical study in freely-behaving rats.
    Brain Res. 1996 Apr 9;715(1-2):86-97 PMID: 8739626
  68. Cytokines, p38 MAP kinase and the pathophysiology of depression.
    Neuropsychopharmacology. 2006 Oct;31(10):2089-90 PMID: 16980982
  69. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.
    Nat Genet. 2000 Apr;24(4):410-4 PMID: 10742108
  70. Interferon-induced depression: prevalence and management.
    Dig Liver Dis. 2005 Feb;37(2):102-7 PMID: 15733522
  71. Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum.
    Neurochem Int. 2001 Apr;38(4):303-8 PMID: 11137624
  72. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects.
    Arch Gen Psychiatry. 2003 Aug;60(8):804-15 PMID: 12912764
  73. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.
    FASEB J. 2006 Apr;20(6):670-82 PMID: 16581975
  74. Neuropsychiatric adverse effects of interferon-alpha: recognition and management.
    CNS Drugs. 2005;19(2):105-23 PMID: 15697325
  75. Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine.
    J Neuroimmune Pharmacol. 2006 Sep;1(3):212-22 PMID: 18040799
  76. Endocrine, cognitive and hippocampal/cortical 5HT 1A/2A receptor changes evoked by a time-dependent sensitisation (TDS) stress model in rats.
    Brain Res. 2003 Sep 5;983(1-2):97-107 PMID: 12914970
  77. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms.
    J Clin Psychiatry. 2005 Aug;66(8):1050-7 PMID: 16086622
  78. Treatment of neurotoxic side effects of interferon-alpha with naltrexone.
    Cancer Invest. 1995;13(6):561-6 PMID: 7583704
  79. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysaccharide-induced alterations to reward behavior and corticosterone release.
    Behav Brain Res. 2004 Feb 4;149(1):77-85 PMID: 14739012
  80. Evidence for an immune response in major depression: a review and hypothesis.
    Prog Neuropsychopharmacol Biol Psychiatry. 1995 Jan;19(1):11-38 PMID: 7708925
  81. Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2.
    Endocrinology. 2001 Nov;142(11):4946-55 PMID: 11606463
  82. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro.
    Neuroendocrinology. 1993 Mar;57(3):489-95 PMID: 8391662
  83. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
    Mol Psychiatry. 2006 Jul;11(7):680-4 PMID: 16491133
  84. Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission.
    J Neurosci. 2002 Dec 15;22(24):10529-32 PMID: 12486144
  85. Effects of interleukin-1beta on food-maintained behavior in the mouse.
    Brain Behav Immun. 2002 Aug;16(4):398-410 PMID: 12096886
  86. Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures.
    Int J Neuropsychopharmacol. 2006 Feb;9(1):27-35 PMID: 15963243
  87. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms.
    J Psychopharmacol. 2004 Mar;18(1):41-6 PMID: 15107183
  88. Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: comparison with the hypothalamic response.
    Neurochem Int. 1997 Apr-May;30(4-5):455-63 PMID: 9106261
  89. Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients.
    Liver Int. 2007 Oct;27(8):1098-102 PMID: 17845538
  90. A single exposure to restraint stress induces behavioral and neurochemical sensitization to stimulating effects of amphetamine: involvement of NMDA receptors.
    Ann N Y Acad Sci. 2002 Jun;965:233-46 PMID: 12105099
  91. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant.
    J Pharmacol Exp Ther. 2004 Sep;310(3):1216-25 PMID: 15082752
  92. IL-6 levels decrease with SSRI treatment in patients with major depression.
    Hum Psychopharmacol. 2005 Oct;20(7):473-6 PMID: 16158446
  93. Anhedonic and anxiogenic effects of cytokine exposure.
    Adv Exp Med Biol. 1999;461:199-233 PMID: 10442175
  94. Neurotransmitter changes by interferon-alpha and therapeutic implications.
    Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S203-6 PMID: 14677080
  95. T-lymphocyte activation increases hypothalamic and amygdaloid expression of CRH mRNA and emotional reactivity to novelty.
    J Neurosci. 1999 Jun 1;19(11):4533-43 PMID: 10341253
  96. Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala.
    J Neurosci. 1998 Jun 15;18(12):4758-66 PMID: 9614249
  97. Neurotrophins and depression.
    Trends Pharmacol Sci. 1999 Feb;20(2):59-61 PMID: 10101965
  98. IL-1beta regulation of BDNF expression in rat cultured hypothalamic neurons depends on the presence of glial cells.
    Neurochem Int. 2006 Oct;49(5):433-41 PMID: 16621158
  99. IFN-induced depression: a role for NSAIDs.
    Psychopharmacol Bull. 2003 Summer;37(3):29-50 PMID: 14608239
  100. Sensitization associated with stressors and cytokine treatments.
    Brain Behav Immun. 2003 Apr;17(2):86-93 PMID: 12676571
  101. How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitary-adrenal axis.
    Psychoneuroendocrinology. 2001 Nov;26(8):761-88 PMID: 11585678
  102. Molecular mechanisms of cytokine-induced neuroprotection: NFkappaB and neuroplasticity.
    Curr Pharm Des. 2005;11(8):985-98 PMID: 15777249
  103. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier.
    Brain Res. 2003 Jul 18;978(1-2):104-14 PMID: 12834904
  104. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.
    Neuropsychopharmacology. 2001 Feb;24(2):130-40 PMID: 11120395
  105. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.
    J Affect Disord. 2007 Nov;103(1-3):83-90 PMID: 17292481
  106. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders.
    Prog Neurobiol. 2008 May;85(1):1-74 PMID: 18346832
  107. The antidepressant and antiinflammatory effects of rolipram in the central nervous system.
    CNS Drug Rev. 2001 Winter;7(4):387-98 PMID: 11830756
  108. Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat.
    J Neurosci. 1995 Mar;15(3 Pt 1):1961-70 PMID: 7891145
  109. Immune correlates of depression.
    Adv Exp Med Biol. 1999;461:1-24 PMID: 10442164
  110. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans.
    Int J Neuropsychopharmacol. 2002 Dec;5(4):375-88 PMID: 12466036
  111. Effect of cyclooxygenase inhibitors on the CRH-induced pituitary-adrenocortical activity during crowding stress.
    J Physiol Pharmacol. 2003 Mar;54(1):99-108 PMID: 12674222
  112. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration.
    Endocr J. 1995 Aug;42(4):551-6 PMID: 8556063
  113. Influence of poly I:C on sickness behaviors, plasma cytokines, corticosterone and central monoamine activity: moderation by social stressors.
    Brain Behav Immun. 2007 May;21(4):477-89 PMID: 17267173
  114. The JAK-STAT signaling pathway: input and output integration.
    J Immunol. 2007 Mar 1;178(5):2623-9 PMID: 17312100
  115. Cytokines sing the blues: inflammation and the pathogenesis of depression.
    Trends Immunol. 2006 Jan;27(1):24-31 PMID: 16316783
  116. Levels of neurotrophic factors in the hippocampus and amygdala correlate with anxiety- and fear-related behaviour in C57BL6 mice.
    J Neural Transm (Vienna). 2007;114(4):431-44 PMID: 16897598
  117. Basic fibroblast growth factor as a mediator of the effects of glutamate in the development of long-lasting sensitization to stimulant drugs: studies in the rat.
    Psychopharmacology (Berl). 2000 Aug;151(2-3):152-65 PMID: 10972461
  118. Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations.
    J Neuroimmunol. 2007 May;186(1-2):45-53 PMID: 17428549
  119. Influence of forced swimming stress on 5-HT1A receptors and serotonin levels in mouse brain.
    Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):275-81 PMID: 15694235
  120. Neuroendocrine effects of interferon-alpha in the rat.
    Adv Exp Med Biol. 1995;373:209-18 PMID: 7668154
  121. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder.
    Psychopharmacology (Berl). 2003 Dec;170(4):429-33 PMID: 12955291
  122. The role of the amygdala in fear and anxiety.
    Annu Rev Neurosci. 1992;15:353-75 PMID: 1575447
  123. Dissociating anorexia and anhedonia elicited by interleukin-1beta: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake.
    Psychopharmacology (Berl). 2003 Feb;165(4):413-8 PMID: 12459927
  124. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes.
    J Neuroimmunol. 2005 Mar;160(1-2):204-9 PMID: 15710474
  125. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli.
    Proc Soc Exp Biol Med. 2000 Jan;223(1):22-38 PMID: 10632958
  126. The immune system as a sensory organ.
    J Immunol. 1984 Mar;132(3):1067-70 PMID: 6363533
  127. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter.
    Eur J Pharmacol. 1998 May 22;349(2-3):317-24 PMID: 9671113
  128. Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study.
    J Neurosci. 1995 Apr;15(4):2920-34 PMID: 7536823
  129. Altered RNA editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy.
    Brain Res Mol Brain Res. 2004 Apr 29;124(1):70-8 PMID: 15093687
  130. Lipopolysaccharide and interleukin-1 depress food-motivated behavior in mice by a vagal-mediated mechanism.
    Brain Behav Immun. 1995 Sep;9(3):242-6 PMID: 8590821
  131. Cytokine-associated emotional and cognitive disturbances in humans.
    Arch Gen Psychiatry. 2001 May;58(5):445-52 PMID: 11343523
  132. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C.
    Acta Psychiatr Scand. 2004 Feb;109(2):126-31 PMID: 14725594
  133. Central mediation of the effects of interleukin-1 on social exploration and body weight in mice.
    Psychoneuroendocrinology. 1997 Jan;22(1):1-11 PMID: 9141147
  134. The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat.
    J Trauma. 2006 Jan;60(1):152-7 PMID: 16456449
  135. The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system.
    J Affect Disord. 2001 Mar;63(1-3):85-92 PMID: 11246084
  136. Long-term effects of social stress on brain and behavior: a focus on hippocampal functioning.
    Neurosci Biobehav Rev. 2005 Feb;29(1):83-97 PMID: 15652257
  137. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.
    Mol Psychiatry. 2002;7(5):468-73 PMID: 12082564
  138. Early increase in mRNA levels of pro-inflammatory cytokines and their interactions in the mouse hippocampus after transient global ischemia.
    Neurosci Lett. 2006 Jan 30;393(2-3):122-6 PMID: 16356636
  139. Cytokine activation of the HPA axis.
    Ann N Y Acad Sci. 2000;917:608-17 PMID: 11268389
  140. Mutagenesis and knockout models: hypothalamic-pituitary-adrenocortical system.
    Handb Exp Pharmacol. 2005;(169):113-41 PMID: 16594256
  141. Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations.
    Neuropsychopharmacology. 2000 Jun;22(6):566-80 PMID: 10788757
  142. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders.
    Trends Neurosci. 2004 Oct;27(10):589-94 PMID: 15374669
  143. Psychological stress increased corticotropin-releasing hormone mRNA and content in the central nucleus of the amygdala but not in the hypothalamic paraventricular nucleus in the rat.
    Brain Res. 1999 Dec 11;850(1-2):136-43 PMID: 10629757
  144. From inflammation to sickness and depression: when the immune system subjugates the brain.
    Nat Rev Neurosci. 2008 Jan;9(1):46-56 PMID: 18073775
  145. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression.
    Brain Behav Immun. 2007 Jan;21(1):9-19 PMID: 17070667
  146. The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels.
    Pharmacol Biochem Behav. 2002 Apr;71(4):857-65 PMID: 11888576
  147. Stressor controllability modulates stress-induced dopamine and serotonin efflux and morphine-induced serotonin efflux in the medial prefrontal cortex.
    Neuropsychopharmacology. 2003 Sep;28(9):1589-96 PMID: 12784102
  148. Systemic cytokine administration can affect blood-brain barrier permeability in the rat.
    Life Sci. 1995;56(10):775-84 PMID: 7885193
  149. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
    Brain Behav Immun. 2004 May;18(3):205-13 PMID: 15050647
  150. Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-alpha: peripheral and central mechanisms.
    Eur J Neurosci. 2002 Mar;15(6):1061-76 PMID: 11918665
  151. Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat.
    J Neuroendocrinol. 2000 Aug;12(8):766-73 PMID: 10929089
  152. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1.
    Brain Res. 1999 Jul 17;835(1):1-9 PMID: 10448190
  153. Inflammatory blockade restores adult hippocampal neurogenesis.
    Science. 2003 Dec 5;302(5651):1760-5 PMID: 14615545
  154. Annual review prize lecture cytokines - killers in the brain?
    J Physiol. 1999 Jan 1;514 ( Pt 1):3-17 PMID: 9831712
  155. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research.
    Psychol Bull. 2004 May;130(3):355-91 PMID: 15122924
  156. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    Nat Clin Pract Rheumatol. 2007 Apr;3(4):227-33 PMID: 17396108
  157. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression.
    Curr Opin Pharmacol. 2002 Feb;2(1):23-33 PMID: 11786305
  158. Site-specific modulation of LPS-induced fever and interleukin-1 beta expression in rats by interleukin-10.
    Am J Physiol Regul Integr Comp Physiol. 2002 Jun;282(6):R1762-72 PMID: 12010759
  159. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
    Aliment Pharmacol Ther. 2007 May 15;25(10):1163-74 PMID: 17451562
  160. Brain monoamine receptors in a chronic unpredictable stress model in rats.
    J Neural Transm (Vienna). 2001;108(3):311-9 PMID: 11341483
  161. Differential regulation of serotonin (5HT)2A receptor mRNA and protein levels after single and repeated stress in rat brain: role in learned helplessness behavior.
    Neuropharmacology. 2005 Feb;48(2):204-14 PMID: 15695159
  162. Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6.
    J Psychopharmacol. 2002 Sep;16(3):230-4 PMID: 12236630
  163. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
    Brain Res. 2001 Jan 5;888(1):117-127 PMID: 11146058
  164. Central monoamine activity in genetically distinct strains of mice following a psychogenic stressor: effects of predator exposure.
    Brain Res. 2001 Feb 23;892(2):293-300 PMID: 11172776
  165. The cellular neurobiology of depression.
    Nat Med. 2001 May;7(5):541-7 PMID: 11329053
  166. Cross-sensitization between immune and non-immune stressors. A role in the etiology of depression?
    Adv Exp Med Biol. 1999;461:179-97 PMID: 10442174
  167. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments.
    J Affect Disord. 2008 Jan;105(1-3):279-83 PMID: 17553570
  168. Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormone in vivo.
    Lymphokine Cytokine Res. 1991 Apr;10(1-2):141-6 PMID: 1651767
  169. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.
    Am J Psychiatry. 2003 Jul;160(7):1342-5 PMID: 12832253
  170. The phenomenology and treatment of interferon-induced depression.
    J Affect Disord. 2004 Oct 15;82(2):175-90 PMID: 15488246
  171. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition.
    Psychol Rev. 1998 Jan;105(1):83-107 PMID: 9450372
  172. Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity.
    J Neurosci. 2006 Oct 11;26(41):10387-96 PMID: 17035523
  173. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder.
    Am J Psychiatry. 1992 Aug;149(8):999-1010 PMID: 1353322
  174. Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock.
    Neuropsychopharmacology. 2002 Aug;27(2):133-42 PMID: 12093587
  175. Effect of continuous intravenous injection of interleukin-6 and pretreatment with cyclooxygenase inhibitor on brain c-fos expression in the rat.
    Neuroendocrinology. 1997 Jul;66(1):47-53 PMID: 9258918
  176. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
    Mol Psychiatry. 2005 Jun;10(6):538-44 PMID: 15494706
  177. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.
    Ann N Y Acad Sci. 1995 Jul 21;762:474-6 PMID: 7668562
  178. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell.
    Biochem Biophys Res Commun. 2006 May 5;343(2):391-400 PMID: 16545775
  179. Exposure to acute stress induces brain interleukin-1beta protein in the rat.
    J Neurosci. 1998 Mar 15;18(6):2239-46 PMID: 9482808
  180. Effects of intraperitoneal administration of IFN-alpha for one, four, and fourteen days on amino acid levels in various rat brain regions.
    J Interferon Cytokine Res. 2005 Apr;25(4):187-91 PMID: 15812244
  181. NF-kappaB p50-deficient mice show reduced anxiety-like behaviors in tests of exploratory drive and anxiety.
    Behav Brain Res. 2004 Oct 5;154(2):577-84 PMID: 15313047
  182. Death receptors: signaling and modulation.
    Science. 1998 Aug 28;281(5381):1305-8 PMID: 9721089
  183. Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks.
    World J Gastroenterol. 2007 Nov 21;13(43):5736-40 PMID: 17963300
  184. Effects of interleukin-1beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study.
    Brain Res. 1997 Jul 4;761(2):225-35 PMID: 9252020
  185. Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses.
    J Neurosci. 2003 Jun 15;23(12):5295-301 PMID: 12832554
  186. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.
    J Psychiatr Res. 1999 Sep-Oct;33(5):407-18 PMID: 10504009
  187. Differential effects of interleukin (IL)-1beta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation.
    Brain Res. 1998 Jan 1;779(1-2):177-87 PMID: 9473665
  188. Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia.
    Neuroreport. 1998 Dec 1;9(17):3797-802 PMID: 9875707
  189. Alternative signaling pathways regulating type I interferon-induced apoptosis.
    J Interferon Cytokine Res. 2005 Dec;25(12):799-810 PMID: 16375608
  190. A neuroendocrine mechanism for sustaining fear.
    Trends Neurosci. 2005 Dec;28(12):629-35 PMID: 16214230
  191. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier.
    Neuroscience. 1999;93(4):1449-64 PMID: 10501470
  192. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants.
    J Psychiatr Res. 2008 Jun;42(7):521-5 PMID: 17585940
  193. Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study.
    Brain Res. 1996 May 20;721(1-2):140-9 PMID: 8793094
  194. Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders.
    J Neurovirol. 1999 Dec;5(6):538-55 PMID: 10602396
  195. Time-dependent behavioral, neurochemical, and immune consequences of repeated experiences of social defeat stress in male mice and the ameliorative effects of fluoxetine.
    Brain Behav Immun. 2005 Nov;19(6):530-9 PMID: 16214024
  196. Physiology and neurobiology of stress and adaptation: central role of the brain.
    Physiol Rev. 2007 Jul;87(3):873-904 PMID: 17615391
  197. Role of paroxetine in interferon-alpha-induced immune and behavioural changes in male Wistar rats.
    J Psychopharmacol. 2007 Nov;21(8):843-50 PMID: 17984161
  198. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development.
    Neuron. 1998 Jun;20(6):1093-102 PMID: 9655498
  199. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6.
    Brain Res. 1994 Apr 18;643(1-2):40-9 PMID: 7518332
  200. NF-kappaB signaling in lymphocytes: a new cast of characters.
    J Cell Sci. 2004 Jan 1;117(Pt 1):31-9 PMID: 14657271
  201. Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats.
    Biol Psychiatry. 2003 Jul 1;54(1):59-69 PMID: 12842309
  202. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus.
    J Neurosci. 1993 Aug;13(8):3574-81 PMID: 8393485
  203. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain.
    Brain Res. 1997 Feb 7;747(2):348-51 PMID: 9046014
  204. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice.
    Int Immunopharmacol. 2006 Jun;6(6):903-7 PMID: 16644475
  205. Interleukin-1-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)--neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis.
    J Neurosci. 1995 Nov;15(11):7417-26 PMID: 7472494
  206. BDNF mRNA expression in rat hippocampus following contextual learning is blocked by intrahippocampal IL-1beta administration.
    J Neuroimmunol. 2004 Oct;155(1-2):119-26 PMID: 15342202
  207. Interleukin-1 beta production in dysthymia before and after pharmacotherapy.
    Biol Psychiatry. 1999 Dec 15;46(12):1649-55 PMID: 10624546
  208. Major depression and activation of the inflammatory response system.
    Adv Exp Med Biol. 1999;461:25-46 PMID: 10442165
  209. Emotion circuits in the brain.
    Annu Rev Neurosci. 2000;23:155-84 PMID: 10845062
  210. Brain distribution of cytokine mRNA induced by systemic administration of interleukin-1beta or tumor necrosis factor alpha.
    Brain Res. 2006 Nov 20;1120(1):64-73 PMID: 17022949
  211. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis.
    Trends Neurosci. 1997 Feb;20(2):78-84 PMID: 9023876
  212. A detailed examination of cytokine abnormalities in Major Depressive Disorder.
    Eur Neuropsychopharmacol. 2008 Mar;18(3):230-3 PMID: 17681762
  213. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions.
    Mol Psychiatry. 1996 Sep;1(4):336-42 PMID: 9118360
  214. Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-alpha.
    Neuroscience. 2001;106(1):137-48 PMID: 11564424
  215. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
    Neuropsychopharmacology. 2002 May;26(5):643-52 PMID: 11927189
  216. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
    J Pharmacol Exp Ther. 1998 Nov;287(2):705-11 PMID: 9808700
  217. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
    J Clin Psychopharmacol. 2002 Feb;22(1):86-90 PMID: 11799348
  218. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects.
    J Neurosci. 2003 Jan 1;23(1):349-57 PMID: 12514234
  219. Physiological and behavioral responses to interleukin-1beta and LPS in vagotomized mice.
    Physiol Behav. 2005 Jul 21;85(4):500-11 PMID: 15996692
  220. Sertraline treatment of interferon-alfa-induced depressive disorder.
    Med J Aust. 2000 Oct 2;173(7):359-61 PMID: 11062791
  221. Acute inflammation and negative mood: mediation by cytokine activation.
    Brain Behav Immun. 2005 Jul;19(4):345-50 PMID: 15944074
  222. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats.
    Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):781-92 PMID: 15927336
  223. The relationship of depression and stressors to immunological assays: a meta-analytic review.
    Brain Behav Immun. 2001 Sep;15(3):199-226 PMID: 11566046
  224. Early-life exposure to endotoxin alters hypothalamic-pituitary-adrenal function and predisposition to inflammation.
    Proc Natl Acad Sci U S A. 2000 May 9;97(10):5645-50 PMID: 10779563
  225. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor.
    Neurosci Biobehav Rev. 2005;29(4-5):829-41 PMID: 15893820
  226. Stress-induced sensitization of dopamine and norepinephrine efflux in medial prefrontal cortex of the rat.
    J Neurochem. 1994 Aug;63(2):575-83 PMID: 8035182
  227. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression.
    J Psychiatry Neurosci. 2004 Jan;29(1):11-7 PMID: 14719046
  228. Expression of the p75 TNF receptor is linked to TNF-induced NFkappaB translocation and oxyradical neutralization in glial cells.
    Neurochem Res. 2002 Nov;27(11):1535-42 PMID: 12512958
  229. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.
    Eur J Pharmacol. 1997 Mar 26;323(1):21-6 PMID: 9105872
  230. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
    Pharmacol Ther. 2006 May;110(2):135-370 PMID: 16522330
  231. Learned helplessness increases 5-hydroxytryptamine1B receptor mRNA levels in the rat dorsal raphe nucleus.
    Biol Psychiatry. 1997 Mar 15;41(6):668-74 PMID: 9066990
  232. Distinct neurochemical populations in the rat central nucleus of the amygdala and bed nucleus of the stria terminalis: evidence for their selective activation by interleukin-1beta.
    J Comp Neurol. 1999 Oct 11;413(1):113-28 PMID: 10464374
  233. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects.
    Br J Clin Pharmacol. 2003 Jun;55(6):591-5 PMID: 12814454
  234. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1.
    Nat Genet. 1998 Jun;19(2):162-6 PMID: 9620773
  235. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder.
    Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):445-50 PMID: 17976882
  236. Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus.
    Nat Neurosci. 2005 Mar;8(3):365-71 PMID: 15696163
Article Info
Journal
Journal of psychiatry & neuroscience : JPN
Abbr.
J Psychiatry Neurosci
ISSN
1488-2434
Published
2009-01-00
Pages
4-20
Language
English
Region
Canada
NLM ID
9107859
PMCID
PMC2612083
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]